25.81

2.14% +0.54

Insmed Inc (INSM)

Overview News Price History Option Chain Discussions Forecast Stock Split

Insmed Inc stock is currently priced at $25.81, with a 24-hour trading volume of 2.47M. It has seen a +2.14% increased in the last 24 hours and a -2.35% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $25.22 pivot point. If it approaches the $25.88 resistance level, significant changes may occur.

Previous Close:

$25.27

Open:

$25.58

24h Volume:

2.47M

Market Cap:

$3.83B

Revenue:

$305.21M

Net Income/Loss:

$-749.57M

P/E Ratio:

-4.8975

EPS:

-5.27

Net Cash Flow:

$-549.54M

1W Performance:

-1.41%

1M Performance:

-2.35%

6M Performance:

+3.03%

1Y Performance:

+36.49%

1D Range:

$25.34

$25.95

52W Range:

$18.09

$32.00

Insmed Inc Stock (INSM) Company Profile

Name

Insmed Inc

Sector

Healthcare (1198)

Industry

Biotechnology (688)

Phone

908-977-9900

Address

Building 10, 10 Finderne Avenue, Bridgewater, NJ

Employee

214

Twitter

@insmed

Next Earnings Date

2024-05-02

Latest SEC Filings

INSM's Discussions on Twitter

Insmed Inc Stock (INSM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-15-24	Initiated	Wolfe Research	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Nov-20-23	Resumed	JP Morgan	Overweight
Jul-26-23	Initiated	Guggenheim	Buy
Dec-09-22	Initiated	Mizuho	Buy
Dec-07-22	Initiated	Barclays	Overweight
Nov-18-22	Initiated	BofA Securities	Buy
Apr-27-22	Initiated	Goldman	Buy
Dec-06-21	Initiated	JP Morgan	Overweight
Oct-19-21	Resumed	Monness Crespi & Hardt	Buy
Oct-19-21	Resumed	Morgan Stanley	Overweight
Oct-08-21	Initiated	Cantor Fitzgerald	Overweight
Apr-26-21	Resumed	Credit Suisse	Outperform
Dec-17-20	Initiated	Berenberg	Buy
Oct-12-20	Resumed	Stifel	Buy
Sep-03-19	Initiated	Goldman	Buy
Apr-09-19	Reiterated	H.C. Wainwright	Buy
Feb-15-19	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Jan-17-19	Upgrade	Goldman	Neutral → Buy
Jan-02-19	Initiated	Canaccord Genuity	Buy
Aug-06-18	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jul-23-18	Initiated	Goldman	Neutral
Apr-23-18	Upgrade	Credit Suisse	Neutral → Outperform
Mar-21-18	Initiated	Morgan Stanley	Overweight
Jan-18-18	Initiated	Credit Suisse	Neutral
Sep-05-17	Reiterated	Evercore ISI	Outperform
Aug-17-17	Initiated	Evercore ISI	Outperform
Jul-11-17	Initiated	Robert W. Baird	Outperform
Mar-15-16	Initiated	Stifel	Buy
Nov-09-15	Downgrade	UBS	Buy → Neutral
Oct-06-15	Reiterated	H.C. Wainwright	Buy
Jun-09-15	Initiated	Citigroup	Neutral
Mar-26-14	Reiterated	HC Wainwright	Buy

View All

Insmed Inc Stock (INSM) Latest News

Insmed Inc Stock (INSM) Financials Data

Insmed Inc (INSM) Revenue 2024

INSM reported a revenue (TTM) of $305.21 million for the quarter ending December 31, 2023, a +24.39% rise year-over-year.

Insmed Inc (INSM) Net Income 2024

INSM net income (TTM) was -$749.57 million for the quarter ending December 31, 2023, a -55.66% decrease year-over-year.

Insmed Inc (INSM) Cash Flow 2024

INSM recorded a free cash flow (TTM) of -$549.53 million for the quarter ending December 31, 2023, a -33.93% decrease year-over-year.

Insmed Inc (INSM) Earnings per Share 2024

INSM earnings per share (TTM) was -$5.34 for the quarter ending December 31, 2023, a -36.92% decline year-over-year.

Insmed Inc Stock (INSM) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Adsett Roger	Chief Operating Officer	Jan 12 '24	Sale	28.63	5,251	150,336	148,559
Flammer Martina M.D.	Chief Medical Officer	Jan 12 '24	Sale	28.63	4,667	133,616	106,898
Adsett Roger	Chief Operating Officer	Jan 10 '24	Sale	28.90	3,536	102,190	153,810
Flammer Martina M.D.	Chief Medical Officer	Jan 10 '24	Sale	28.90	1,245	35,980	111,565
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Jan 09 '24	Option Exercise	20.49	503	10,306	105,652
Lewis William	Chair and CEO	Jan 09 '24	Sale	28.72	9,887	283,955	363,651
Flammer Martina M.D.	Chief Medical Officer	Jan 09 '24	Sale	29.01	4,715	136,782	112,810
Bonstein Sara	Chief Financial Officer	Jan 09 '24	Sale	29.18	4,497	131,222	114,051
Adsett Roger	Chief Operating Officer	Jan 09 '24	Sale	29.25	3,837	112,232	157,346
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Jan 09 '24	Sale	28.85	3,668	105,831	101,984

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex. Its earlier-stage clinical pipeline also includes INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug for rare pulmonary disorders. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.